Lifestyle medicine interventions, such as dietary changes, movement and mindfulness, in combination with conventional treatment, may help alleviate symptoms of rheumatic disease, according to panelists at ACR Convergence 2023.
Search results for: fatigue
FDA Approves Sarilumab for Adults with Glucocorticoid-Resistant Polymyalgia Rheumatica
On Feb. 28, 2023, the U.S. Food & Drug Administration (FDA) approved sarilumab (Kevzara) for the treatment of adults with polymyalgia rheumatica (PMR) for whom glucocorticoids have proved inadequate or who cannot tolerate a glucocorticoid taper.1,2 Sarilumab is an interleukin (IL) 6 receptor antagonist. In May 2017, the FDA initially approved the agent for the…
How to Treat Refractory Polymyalgia Rheumatica
Patients with polymyalgia rheumatica (PMR) who had relapsed while tapering glucocorticoid therapy were more likely to achieve sustained remission at one year and have a lower glucocorticoid exposure if they were treated with sarilumab (Kevzara) plus a rapid, 14-week glucocorticoid taper than if they received placebo plus a standard, 52-week glucocorticoid taper. This is according…
The 2023 ARP Merit Awards
SAN DIEGO—During ACR Convergence 2023 in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP Merit Awards and ARP Master class, recognizing outstanding contributions to the field of rheumatology. The…
An Interview with Expert Clinician Dr. Fred Wigley
Rheumatologists who are outstanding researchers, educators and/or clinicians, who provide consistently exceptional care to patients, who have achieved a level of distinction in the field and who serve as role models for colleagues and trainees are highlighted in this recurring series. Fred Wigley, MD, MACR, is the Martha McCrory Professor of Medicine at the Johns…
Insight into the FDA Approval of Ustekinumab Biosimilar
In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.
Guidelines for ILD in Systemic Autoimmune Rheumatic Diseases
SAN DIEGO—In a scientific session at ACR Convergence 2023, Sindhu Johnson, MD, PhD, and Dinesh Khanna, MD, MSc, discussed ACR’s new guideline on SARDs and ILD.
Rheumatic Disease & Reproductive Health
SAN DIEGO—In the Review Course at ACR Convergence 2023, Dr. Megan Clowse spoke on the subject of reproductive counseling for patients with rheumatic conditions, a topic that has been the focus of much of her research and scholarship.
ARP Welcomes a New President: A Conversation with Aileen Ledingham, PT, MS, PhD
With roots in physical therapy & rehabilitation research, Dr. Ledingham brings to the ARP a deep enthusiasm for volunteering & collaboration, as well as a commitment to building public knowledge about the field of rheumatology.
Beyond the Clinic: Lessons Learned from a Rheumatologist with RA
A pediatric rheumatologist diagnosed with RA following the birth of her first child talks about integrative care & offers tips for helping patients reduce the symptom burden.
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 63
- Next Page »